Equities

Immunitybio Inc

Immunitybio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.83
  • Today's Change-0.12 / -2.42%
  • Shares traded4.15m
  • 1 Year change+40.41%
  • Beta0.7453
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
OPERATIONS
Net income(584)(417)(350)
Depreciation/depletion191814
Non-Cash items1957080
Cash taxes paid, supplemental0.010.000.01
Cash interest paid, supplemental77352.11
Changes in working capital3.98(8)(19)
Total cash from operations(367)(338)(274)
INVESTING
Capital expenditures(31)(99)(34)
Other investing and cash flow items, total0.11127(51)
Total cash from investing(30)27(85)
FINANCING
Financing cash flow items0(0.34)1.02
Total cash dividends paid------
Issuance (retirement) of stock, net10760166
Issuance (retirement) of debt, net451174339
Total cash from financing558234505
NET CHANGE IN CASH
Foreign exchange effects(0.29)0.280.05
Net change in cash161(76)146
Net cash-begin balance/reserved for future use10518135
Net cash-end balance/reserved for future use266105181
SUPPLEMENTAL INCOME
Depreciation, supplemental191814
Cash interest paid, supplemental77352.11
Cash taxes paid, supplemental0.010.000.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.